New drug cocktail targets rare, aggressive kidney cancer
NCT ID NCT03587662
First seen Jun 24, 2026 · Last updated Aug 12, 2026 · Updated 5 times
Summary
This phase II trial is testing whether combining the targeted drug ixazomib with two chemotherapy drugs (gemcitabine and doxorubicin) can shrink tumors or stop them from growing in patients with a rare and aggressive kidney cancer called renal medullary carcinoma. The study enrolls 30 adults whose cancer has spread. Researchers will measure how many patients respond and track side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ixazomib, gemcitabine, and doxorubicin
- What this could lead to
- If successful, this could offer a new treatment option for a rare and aggressive kidney cancer that currently has few effective therapies.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to all patients. The combination therapy may cause significant side effects and may not shrink tumors as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT-ONSET MALIGNANT RHABDOID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- Immunotherapy after kidney surgery may delay cancer return in rare kidney cancer
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- Radiation boosts immunotherapy in kidney cancer trial